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Objective: The management of malignant pericardial effusion remains 
controversial. We present our experience with 93 patients referred for 
drainage and sclerosing procedures between 1979 and 1994. Methods: With 
continuous electrocardiographic monitoring, a Kifa catheter was inserted 
percutaneously into the pericardial sac and allowed to drain. A 100 mg dose 
of lidocaine hydrochloride was instilled intrapericardially, followed by 500 
to 1000 mg tetracycline or doxycycline hydrochloride in 20 to 50 ml normal 
saline solution. The catheter was clamped for 1 to 2 hours and then 
reopened, and the procedure was repeated aily until the net drainage was 
less than 25 ml in 24 hours. Results: Subjects included 53 women and 40 
men (median age 58 years). Eight patients could not undergo sclerosis 
because of technical failure. Eighty-five patients underwent sclerosis and 
required a median dose of 1500 mg of the sclerosing agent (range 500 to 700 
mg), given in a median of three injections (range one to eight). Complica- 
tions included pain (17 patients), atrial arrhythmias (eight patients), fever 
with temperature greater than 38.5 ° C (seven patients), and infection (one 
patient). Two patients had cardiac arrest before sclerosis could be at- 
tempted. Sixty-eight patients (73%) had the effusion controlled for longer 
than 30 days, for an overall control rate of 81%. Seven other patients had 
control of the effusion but died of progressive malignant disease in less than 
30 days. The overall median survival was 98 days (range 1 to 1724 days). 
Comparison of these results with outcomes reported for patients with 
malignant pericardial effusion who underwent surgical drainage indicates 
that drainage and sclerosis provide similar survivals but sclerosis carries 
lower morbidity, mortality, and recurrence rates. Conclusion: Percutaneous 
drainage and sclerosis constitutes a safe and effective treatment for 
malignant pericardial effusion. Surgical management should be reserved 
for the small percentage of cases that cannot be controlled by this method. 
(J Thorac Cardiovasc Surg 1996;112:637-43) 
T he incidence of pericardial involvement as a complication of malignancy has been reported to 
range from as low as 0.1% in clinical studies to 21% 
in some autopsy series. 1Malignant pericardial effu- 
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sion (MPE) is frequently not suspected until the 
signs and symptoms of cardiac tamponade develop; 
at this stage, this complication of malignancy is 
potentially fatal unless promptly treated. Treatment 
of this oncologic emergency, however, often results 
in good palliation of symptoms and prolongation of 
survival. 2
Several studies have shown that tetracycline scle- 
rosis is a safe and effective treatment for MPE. 3' 4 
Recent reports, however, continue to suggest hat a 
surgical approach, either subxiphoid drainage with 
or without window formation or a limited pericar- 
diotomy, should be the initial treatment for MPE. 5-7 
The development of thoracoscopy has permitted 
more ready surgical access to the pericardium, and 
recent reports recommend this approach?' 9 For the 
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Table I. Characteristics of93 patients with MPE 
No. % 
Sex 
Male 40 43 
Female 53 57 
Age (yr) 
Median 58 
Range 24 -77 
Primary tumor 
Lung 45 48 
Breast 26 28 
Adenocarcinoma of unknown origin 8 9 
Mesothelioma 6 7 
Stomach 3 3 
Lymphoma 2 2 
Leukemia 1 1 
Ovary 1 1 
Sarcoma 1 1 
Cytologic examination 
Positive 69 77 
Negative 21 23 
Not done 3 3 
past 15 years, patients with cardiac tamponade 
arising from MPE have been treated medically in 
our institution with percutaneous drainage and tet- 
racycline sclerosis of the pericardial sac. We present 
here our updated experience with tetracycline scle- 
rosis and compare our results with outcomes re- 
ported in the surgical iterature. 
Methods 
We reviewed the records of 99 patients with MPE seen 
at our institution between January 1, 1979, and March 1, 
1994. Of these patients, 93 were referred for drainage and 
tetracycline or doxycycline sclerosis of the pericardial space. 
Baseline investigations for all patients included history, 
physical examination, chest radiography, electrocardiog- 
raphy, and two-dimensional echocardiography. After 
echocardiographic confirmation of the presence of peri- 
cardial effusion, patients were taken to the cardiac care 
unit for electrocardiographic monitoring. Under sterile 
conditions, a 6.5F Kifa catheter (Cook Incorporated, 
Bloomington, Ind.) was inserted percutaneously through a
subxiphoid approach into the pericardial sac by means of 
the Seldinger technique. The catheter was then connected 
to a Hemovac system (Zimmer, Patient Care Div., Dover, 
Ohio) with a three-way stopcock and left in place to drain. 
When patients were in hemodynamically stable condi- 
tion, they were transferred tothe general medical ward for 
the sclerosing procedure. To prevent pain, 100 mg lido- 
caine hydrochloride was injected intrapericardially before 
instillation of the sclerosing agent. Either 500 to 1000 mg 
tetracycline hydrochloride (80 patients) or 500 to 1000 mg 
doxycycline hydrochloride (five patients) was dissolved in 
10 to 20 ml normal saline solution and inserted through 
the catheter into the pericardial sac. The catheter was 
clamped for 1 to 2 hours and then reopened and allowed 
to drain to the Hemovac system. Special positioning of the 
patient was not required. This procedure was repeated every 
24 to 48 hours, until the net drainage was less than 25 ml/24 
hours. The catheter was removed only after echocardiogra- 
phy confirmed that the effusion had resolved. Patient fol- 
low-up after sclerosis was predominantly b means of phys- 
ical examination and chest radiography. Echocardiography 
was repeated as clinically indicated. 
Pericardial f uid from the initial pericardiocentesis was 
examined for protein, cell count, cytologic haracteristics, 
and culture. Treatment outcome was evaluated according 
to the criteria of Smith, Lane, and Hudgins. 1° Successful 
treatment was defined as follows: (1) reduction or resolu- 
tion of the effusion for a minimum of 30 days, (2) the 
absence of symptoms, and (3) no requirement for pericar- 
diocentesis within 30 days of initiation of treatment. 
Survival time was calculated from the date of first instil- 
lation of the sclerosing agent o the date of death or most 
recent follow-up. 
Results 
Of the 99 patients, three underwent pericardio- 
centesis alone and three who had neither clinical nor 
echocardiographic evidence of tamponade did not 
have their effusions drained. The remaining 93 
patients were referred for tetracycline or doxycy- 
cline sclerosis and form the basis of this report. 
The characteristics of the study population are 
presented in Table I. There were 53 women and 40 
men, with a median age of 58 years (range 24 to 77 
years). Carcinoma of the breast and lung accounted 
for 76% of the primary tumors. The remaining 24% 
included adenocarcinoma of unknown origin in 
eight patients (9%), mesothelioma in six patients 
(7%), stomach cancer in three patients (3%), and 
non-Hodgkins lymphoma, Hodgkins lymphoma, 
leukemia, ovarian cancer, and sarcoma in one pa- 
tient each. MPE was diagnosed at the initial presen- 
tation of the malignancy in two patients with lung 
cancer, but MPE was diagnosed several months to 
several years after the first cancer diagnosis in the 
remaining patients. The pericardial fluid was exam- 
ined cytologically in 90 patients and had malignant 
cells in 77% of these cases. All baseline pericardial 
fluid samples were sterile. 
Eight patients had received previous treatment 
for their pericardial effusions. Five patients had 
reaccumulation f fluid after therapeutic pericardio- 
centesis without sclerosis, and three patients were 
treated after failed surgical drainage procedures. 
One of the surgical patients had undergone both 
simple pericardiocentesis and partial pericardiec- 
tomy. A second patient, who had had subxiphoid 
pericardial windows created on two occasions, un- 
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Table II. Clinical presentation of MPE 
No. % 
Symptoms 
Dyspnea 85 91 
Cough 39 42 
Orthopnea 30 32 
Chest pain 19 20 
Peripheral edema 16 17 
Nausea 11 12 
Impaired level of consciousness 5 5 
Diaphoresis 4 4 
Dysphagia 3 3 
Hemoptysis 2 2 
Syncope 2 2 
Facial swelling 2 2 
Signs 
Paradoxic pulse (>10 mm Hg) 58 62 
Elevated jugular venous pressure 47 51 
Tachycardia (>110 beats/min) 40 43 
Systolic BP (<110 mm Hg) 39 42 
Respiratory rate (>20 breaths/min) 33 35 
Kussmal's ign 13 14 
Friction rub 6 6 
Hepatomegaly 2 2 
BP, Blood pressure. 
derwent sclerosis when cardiac tamponade devel- 
oped as a result of a recurrent loculated effusion. 
The third patient had persistent drainage from two 
surgically placed large-bore indwelling drainage 
tubes. 
Dyspnea, the most common presenting symptom 
of MPE, was found in 85 patients (91%; Table II). 
Other common symptoms included cough in 39 
patients (42%), orthopnea in 30 patients (32%), 
chest pain in 19 patients (20%) and peripheral 
edema in 16 patients (17%). When first seen, all 
patients had one or more physical findings sugges- 
tive of cardiac tamponade, with paradoxic pulse 
(62% of patients) and elevated jugular venous pres- 
sure (51% of patients) being the most common. The 
diagnosis of MPE was confirmed by two-dimen- 
sional echocardiography for all patients (Table III). 
Right atrial inversion was present in 61 patients 
(66%) and right ventricular collapse was present in 
46 patients (49%); both are evidence of cardiac 
tamponade. Pericardial metastases were identified 
in 19 patients (20%). 
The classic electrocardiographic finding of elec- 
trical alternans was seen in only four cases; the most 
common finding on electrocardiography was low 
voltage in the limb leads (total amplitude of the 
QRS complex <5 mm), which was seen in 62 
patients (67%). The most common findings on chest 
Table III. Investigation of MPE 
No, % 
Echocardiography 
Moderate to large MPE 93 100 
Right atrial inversion 61 66 
Right ventricular collapse 46 49 
Pcricardial metastases 19 20 
Hypokinetic left ventricle 4 4 
Wall motion not assessed 12 13 
Loculated effusion 1 1 
Electrocardiograph 
Low voltage in limb leads 62 67 
Nonspecific T-wave abnormalities 50 54 
Atrial fibrillation/flutter 13 14 
Atrial premature beats 8 9 
ST-segment elevation 7 8 
Electrical alternans 4 4 
Left bundle branch block 1 1 
Right bundle branch block 1 1 
Normal 3 3 
Not done 2 2 
Chest radiography 
Enlarged heart shadow 75 81 
Pleural effusions 64 69 
Parenchymal malignant disease 38 41 
Congestive heart failure 6 7 
radiography were enlargement of the cardiac silhou- 
ette, found in 75 patients (81%), and pleural effu- 
sions, noted in 38 patients (41%). 
As outlined in Table IV, eight patients (8%) did 
not receive tetracycline or doxycycline sclerosis for 
technical reasons. In five cases, the catheter became 
clotted before sclerosis could be attempted. In one 
case, the catheter could not be inserted; in another, 
the catheter was removed after complete drainage 
but before instillation of tetracycline because of 
discomfort at the catheter site. The eighth patient 
died after a cardiac arrest 1 hour after pericardio- 
centesis, before instillation of tetracycline. The re- 
maining 85 patients received between one and eight 
instillations of tetracycline or doxycycline (median 
three) and a total dose of 500 to 7000 mg (median 
dose 2000 mg). The median number of days re- 
quired for sclerosis was 5 (range 1 to 17). 
The complications of treatment are outlined in 
Table V. Two patients who had severe tamponade 
had cardiac arrests unrelated to sclerosis during 
pericardiocentesis. One patient was resuscitated and 
underwent sclerosis successfully, but the second 
could not be resuscitated. Retrosternal chest pain 
necessitating narcotic analgesia was seen in 17 pa- 
tients (20%). Seven patients had elevation of tem- 
perature to greater than 38.5 ° C. In one patient, 
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Table IV. Tetracycline or doxycycline instillations 
No. of 
patients 
No. ofinstillations (median 3) 
0 8 
1 21 
2 13 
3 21 
4 23 
5 4 
>5 2 
Dose of tetracycline (mg;median 1500mg) 
0 8 
500 7 
700 1 
1000 16 
1500 17 
2000 23 
2500 6 
3000 6 
3500 2 
4000 4 
5000 1 
7000 1 
fever persisted after 24 hours and cultures of drain- 
ing fluid yielded Staphylococcus aureus. Eight pa- 
tients (9%) had transient asymptomatic atrial ar- 
rhythmias (atrial fibrillation or flutter in five 
patients, paroxysmal trial tachycardia in two). The 
catheter became occluded by clot after sclerosis in 
eight patients. These clots was successfully sed by 
urokinase in four patients, by heparin in two pa- 
tients, and by repeated saline solution flushes in one 
patient. No patient had pericardial constriction re- 
lated to sclerosis therapy. 
The results of tetracycline or doxycycline sclerosis 
are presented in Table VI. Of the 93 patients 
referred for sclerosis, eight did not undergo sclerosis 
because of the technical failures described previ- 
ously. Of the remaining 85 patients, 68 (79%) met 
the Smith criteria 1° for control of MPE for longer 
than 30 days. Seven other patients had continuous 
control of the effusions but died of progressive 
malignant disease less than 30 days after sclerosis. 
Overall, 75 (80%) of the original 93 patients (88% 
of those who underwent sclerosis) achieved control 
of MPE, and their overall median survival was 98 
days after sclerosis (range 1 to 1724 days). In these 
cases, all deaths resulted from progression of the 
underlying malignancy and were unrelated to MPE. 
Patients with breast cancer had a median survival of 
131 days (range 6 to 1724 days), compared with 78 
Table V. Complications of tetracycline or 
doxycycline sclerosis 
No. % 
Pain 17 20 
Temperature >38.5 ° C 7 8 
Infection 1 1 
Atrial fibrillation or flutter 6 7 
Paroxysmal trial tachycardia 2 2 
Catheter plugged 8 10 
Development of rub 2 2 
Cardiac arrest before sclerosis 2 2 
days (range 3 to 828 days) for patients with lung 
cancer (p < 0.05). 
Among the 18 patients who did not achieve 
control of their MPE, nine had no further treat- 
ment. Their median survival was 21 days (range <1 
to 285 days). One patient had local radiation to the 
pericardium and survived 46 days; another, who had 
metastatic breast cancer, received chemotherapy 
and survived 455 days. Seven patients underwent 
surgical procedures, which included a total peri- 
cardiectomy for one patient (survival 5 days) and 
pericardial window formation for six. The median 
survival for the seven surgical patients was 21 days 
(range 5 to 90 days). The overall median survival for 
the 18 patients whose sclerosis failed was 21 days. 
Discussion 
The accumulation of fluid in the pericardial space 
is a potentially fatal complication of malignancy if
not recognized early and treated aggressively. It has 
been reported that 36% of patients with metastases 
to the pericardium die as a direct result of pericar- 
dial involvement; in a further 49% of cases, pericar- 
dial involvement contributes significantly to death. 2
The pathogenesis of MPE is thought to involve 
two major mechanisms. 11 Increased fluid may be 
produced from the visceral pericardium as a result 
of direct spread of the tumor to the serosal surface 
and of fluid accumulation i the pericardial space. 
Alternatively, obstruction of lymphatic and venous 
outflow by tumor may cause increased hydrostatic 
pressure, which results in accumulation of fluid. 
Regardless of the mechanism that leads to the 
development of the MPE, the goals of treatment are 
to provide relief of symptoms and to prevent he 
immediate and late complications of this disorder, 
especially fatal cardiac tamponade. 
In most cases, the diagnosis of MPE is made after 
the diagnosis of an underlying malignancy has been 
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Table VI. Results of sclerosis in 93 patients with 
MPE 
No. % 
Technical failure 8 8 
Sclerosis attempted 85 92 
MPE controlled by sclerosis 75 81 
Survived >30 days without recurrence 68 73 
Survived <30 days without recurrence 7 8 
Effusion uncontrolled by sclerosis 11 13 
Primary failure of sclerosis 5 5 
Rapid progression of malignancy 4 4 
Recurrences 3 3 
Salvage procedures 
Pericardial window 7 8 
Pericardiectomy 1 1 
Pericardial radiation 1 1 
Overall survival (days) 
Median 98 
Range 1-1724 
established. 12 This was also the case in our study, in 
which only two patients had MPEs at the time of the 
initial cancer diagnosis. As a result, pericardial 
effusions frequently remain clinically unsuspected 
because the early symptoms may be nonspecific and 
attributed falsely to tumor progression. Further- 
more, when MPE results in cardiac tamponade, the 
predominant symptoms are usually respiratory and 
may initially be attributed to worsening pulmonary 
or pleural metastases. 2' 23, 24 As seen in our study, 
dyspnea, cough, and orthopnea were the most com- 
mon presenting symptoms of MPE. The physical, 
electrocardiographic, and chest radiographic find- 
ings were generally nonspecific. The diagnosis was 
usually suspected when an enlarged cardiac shadow 
was seen on chest radiography; it was then con- 
firmed in each case by echocardiography. All pa- 
tients had a moderate to large pericardial effusion, 
and almost all had echocardiographic evidence of 
tamponade. 
Although simple pericardiocentesis may be life- 
saving, this procedure alone is seldom adequate as 
treatment because it is associated with a high rate of 
reaccumulation f fluid and recurrence of symp- 
toms. is For that reason, pericardiocentesis i  usually 
followed by a definitive medical or surgical proce- 
dure designed to prevent further fluid accumulation 
and to provide an alternative drainage site to pre- 
vent cardiac tamponade. 
Definitive management remains controversial. 
Surgical techniques for the management of MPE 
have evolved considerably during the past decade. 
Pericardiectomy is rarely performed today for MPE 
Table VII. Comparison with published ata 
This 
series Sclerosis* Windowt VATSS; 
No. of patients 93 64 28 49 
Breast and lung (%) 76 60-100 61-100 50-100 
Local anesthetic (%) 100 100 56§ 0 
General anesthetic (%) 0 0 44§ 100 
30-day mortality (%) 7 0-10 18-36 0-38 
Survival (days) 98 104-230 30-90 NA 
Recurrence (%) 3 0-11 0-29 0 
Constriction (%) 0 0 0-10 0 
VATS, Video-assisted thoracoscopic surgery; NA, not applicable. 
*Data included from all patients reported in three studies of pericardiaI 
drainage and tetracycline sclerosis for initial management of MPE between 
1984 and 1991. 3, lo, is 
?Data included from all patients reported in 11 studies of pericardiai 
window formation for initial management of MPE between 1984 and 
19955, 6, 17-25 
.'zData included from all patients reported in seven studies of window 
formation by video-assisted thoracoscopic surgery. 8'9, 26-3o 
§Does not include data from one study in which patients with cancer were 
not separated from total number of patients when reporting percentage of
procedures done with general anesthesia (72%) and local anesthesia 
(28%). 25 
because the operative risks range from 17% to 
30%.16, 17 Recent literature favors the creation of a 
pericardial window either by the subxiphoid route, 
by anterior thoracotomy, or by thoracosco- 
py.8, 9, 17, is Indeed, thoracoscopy has led surgeons 
to a renewed interest in the surgical management of 
MPE, even though this technique requires general 
anesthesia and single-lung ventilation. 9 
We reviewed the results from all surgical series 
published in the last 15 years and extracted the 
outcomes reported for patients who underwent sub- 
xiphoid pericardial window creation with tube drain- 
age 5, 6, 17-25 or drainage by video-assisted thoraco- 
scopic surgery. 8'9, 26-30 We compared the outcomes 
of these two techniques with results from published 
trials of tetracycline sclerosis 3' so, is and with the 
data from our series of 93 patients (Table VII). 
Direct comparison indicates that simple sclerosis 
provides similar survival with lower mortality and 
recurrence rates. The rates of pericardial constric- 
tion with the two procedures are comparable; in- 
deed there are no cases reported after sclerosis, 
whereas our review indicates a 10% constriction rate 
in one study employing the pericardial window 
technique. The follow-up period for the thoraco- 
scopic studies was shorter on average than that 
reported for the other techniques; long-term com- 
plications of recurrence and constriction associated 
with thoracoscopy may thus be underestimated. 
Thoracoscopic pericardial window formation al- 
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lows the surgeon to visualize the pleural space and 
the pericardium and provides the ability to perform 
biopsy procedures when necessary. Thoracoscopy 
may have an advantage in the treatment of undiag- 
nosed malignancy because it provides excellent vi- 
sualization of the thoracic avity and because of the 
ability to perform diagnostic biopsy procedures. 
Most patients with MPE however, have a diagnosis 
of malignancy before the appearance of the effusion 
(96 of 98 in this series). In addition, rate of positive 
results of cytologic examination of pericardial fluid, 
reported to range from 57% to 100% among pa- 
tients with malignancy, 31-33 was 77% in our study. In 
studies that examined the correlation between fluid 
cytologic and pericardial biopsy results, the biopsy 
provided additional information in fewer than 20% 
of cases and failed to make the diagnosis in more 
than 50%. In several studies that compared the 
results of cytologic examination and biopsy, the 
percentage ofpositive biopsy results among patients 
with positive cytologic results ranged from 33% to 
55%, and biopsy results were positive in only 0% to 
21% of patients who had negative cytologic re- 
suits.13, 20-22 
Our review suggests that the major differences 
between medical and surgical management are the 
operative risks associated with surgical procedures. 
Forty-four percent of the subxiphoid window cre- 
ations and 100% of the video-assisted thoracoscopic 
procedures were performed with the patient under 
general anesthesia. Intraoperative complications re- 
ported in several series included hypotension neces- 
sitating inotropic support, 21 pneumothorax, 18 and 
death.S, 20 The development of atrial arrhythmias 
has been reported in both surgical 5 and medical 
series 3, is and was seen in 7% of the cases in our 
series. These arrhythmias were always self-limited 
and never life-threatening. Pain and fever, which 
have been cited as unacceptable accompaniments of 
percutaneous drainage and sclerosis, 19 were seen in 
20% and 7% of patients, respectively, in our series. 
The fever usually lasted less than 24 hours, and an 
organism was cultured from the pericardial fluid in 
only one case in which the catheter emained in 
place for longer than 7 days. Pain was temporally 
related to the injection of the sclerosing agent; 
despite premedication with lidocaine of all patients, 
it was necessary to administer narcotic analgesics to 
17 patients (20%). Pain and fever are also common 
occurrences during the early postoperative period 
after almost all surgical procedures, however, and 
we believe that low rates of these complications are 
reported in the surgical series because they are not 
considered to be complications worthy of note. 
Because the parenteral form of tetracycline is no 
longer commercially available, other sclerosing 
agents are currently under investigation. Both doxy- 
cycline and bleomycin have been used success- 
fully34, 35 in small series, and we are currently un- 
dertaking a prospective comparison of these two 
agents. 
In summary, percutaneous pericardiocentesis and 
tetracycline or doxycycline sclerosis is a safe and 
effective safe treatment for MPE. In patients with 
known malignancy or with positive results of cyto- 
logic examination of pericardial fluid, sclerosis ap- 
pears to be superior to subxiphoid pericardial win- 
dow formation and video-assisted thoracoscopy. 
The latter technique should be reserved for those 
cases that remain undiagnosed after pericardiocen- 
tesis or for the small percentage of cases in which it 
is not possible to control the effusion by percutane- 
ous drainage and sclerosis. 
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